Medine.co.uk

Draft Community Herbal Monograph On Agropyron Repens (L.) P. Beauv., Rhizoma

o

EUROPEAN MEDICINES AGENCY

SCIENCE MEDICINES HEALTH

27 January 2011

EMA/HMPC/563408/2010

Committee on Herbal Medicinal Products (HMPC)

Community herbal monograph on Agropyron repens (L.) P. Beauv., rhizoma

Draft

Herbal medicinal products; HMPC; Community herbal monographs; traditional use; Agropyron repens (L.) P. Beauv., rhizoma; Agropyri repentis rhizoma; couch grass rhizome


BG (balgarski): nwpefi, KopeHM^e CS (cestina): oddenek pyru DA (dansk):

DE (Deutsch): Queckenwurzelstock EL (ellinika):

EN (English): Couch grass rhizome ES (espanol):

ET (eesti keel): orasheina juurikas FI (suomi):

FR (français): chiendent (rhizome de) HU (magyar): Tarackbuza gyôkértôrzs IT (italiano):_


LT (lietuviq kalba):

LV (latviesu valoda): Värpatas saknenis MT (malti):

NL (nederlands): kweek PL (polski): Ktqcze perzu PT (portugués):

RO (romana): rizom de pir SK (slovencina): Pyrovy podzemok SL (slovenscina):

SV (svenska): Kvickrot, jordstam IS (íslenska):

NO (norsk): Kvekerot_


Discussion in Working Party on Community monographs and Community list (MLWP)

November 2010 January 2011

Adoption by Committee on Herbal Medicinal Products (HMPC) for release for consultation

27 January 2011

End of consultation (deadline for comments). Comments should be provided using this template to hmpc.secretariat@ema.europa.eu

15 June 2011

Rediscussion in Working Party on Community monographs and Community list (MLWP)

Adoption by Committee on Herbal Medicinal Products (HMPC)

Keywords

An agency of the European Union


7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 77523 7051 E-mail info@ema.europa.eu Website www.ema.europa.eu

© European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged.

Community herbal monograph on Agropyron repens (L.) P. Beauv., rhizoma

1.    Name of the medicinal product

To be specified for the individual finished product.

2.    Qualitative and quantitative composition1,2

Well-established use

Traditional use

With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended

Agropyron repens (L.) P. Beauv., rhizoma (couch grass rhizome)

i)    Herbal substance Not applicable.

ii)    Herbal preparations

a)    Comminuted herbal substance

b)    Liquid extract (DER 1: 1), extraction solvent ethanol 20-25% V/V

c)    Tincture (ratio of herbal substance to extraction solvent 1:5), extraction solvent ethanol 40% V/V

3. Pharmaceutical form

Well-established use

Traditional use

Comminuted herbal substance as herbal tea for oral use.

Herbal preparations in liquid dosage forms for oral use.

The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

1    The material complies with the Ph. Eur. monograph (ref.: 01/2008:1306 corrected 6.0).

2    The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

4. Clinical particulars

4.1. Therapeutic indications

Well-established use

Traditional use

Traditional herbal medicinal product to increase the amount of urine to achieve flushing of the urinary tract as an adjuvant in minor urinary complaints.

The product is a traditional herbal medicinal product for use in specified indication exclusively based upon long-standing use.

4.2. Posology and method of administration

Well-established use

Traditional use

Posology

Adults and elderly

a)    Comminuted herbal substance as infusion Single dose: 3-6 g

Daily dose: 10-20 g

b)    Liquid extract

Single dose: 4-8 ml, 2 to 4 times daily

c)    Tincture

Single dose: 5-15 ml, 3 times daily

The use in children and adolescents under 18 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').

Duration of use

The herbal substance is traditionally used over a period of 2 up to 4 weeks.

If the symptoms persist during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.

Method of administration

Oral use.

4.3. Contraindications

Well-established use

Traditional use

Hypersensitivity to the active substance(s).

Conditions where a reduced fluid intake is recommended (e.g. severe cardiac or renal disease).

4.4. Special warnings and precautions for use

Well-established use

Traditional use

The use in children and adolescents under 18 years of age is not recommended because of concerns requiring medical advice.

If complaints or symptoms such as fever, dysuria, spasms, or blood in urine occur during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.

For tinctures and extracts containing ethanol, the appropriate labelling for ethanol, taken from the 'Guideline on excipients in the label and package leaflet of medicinal products for human use', must be included.

4.5. Interactions with other medicinal products and other forms of interaction

Well-established use

Traditional use

None reported.

4.6. Pregnancy and lactation

Well-established use

Traditional use

Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended.

4.7. Effects on ability to drive and use machines

Well-established use

Traditional use

No studies on the effect on the ability to drive and use machines have been performed.

4.8. Undesirable effects

Well-established use

Traditional use

None known.

If adverse reactions occur, a doctor or a qualified health care practitioner should be consulted.

4.9. Overdose

Well-established use

Traditional use

No case of overdose has been reported.

5. Pharmacological properties

5.1. Pharmacodynamic properties

Well-established use

Traditional use

Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.2. Pharmacokinetic properties

Well-established use

Traditional use

Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.3. Preclinical safety data

Well-established use

Traditional use

Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product.

Adequate tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.

6. Pharmaceutical particulars

Well-established use

Traditional use

Not applicable.

7. Date of compilation/last revision

27 January

Page 8/6

Community herbal monograph on Agropyron repens (L.) P. Beauv., rhizoma

EMA/HMPC/563408/2010